Nathanael Gray
纳撒尼尔·格雷
PhD
Professor, Department of Chemical and Systems Biology化学与系统生物学系教授
👥Biography 个人简介
Nathanael Gray is a world leader in kinase inhibitor design and targeted protein degradation. His laboratory has produced numerous clinical-stage kinase inhibitors and pioneered PROTAC degraders for oncogenic drivers, expanding the druggable proteome in cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Selective Kinase Inhibitor Development
Designed highly selective inhibitors for kinases including CDK8, FGFR, and mutant EGFR variants, several of which have entered clinical trials for solid tumors.
PROTAC-Based Targeted Protein Degradation
Advanced PROTAC technology for degrading oncogenic kinases including BCR-ABL and BTK mutants, offering advantages over conventional inhibitors in overcoming resistance.
Representative Works 代表性著作
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Nature (2016)
Identified allosteric SHP2 inhibitors with potent anti-tumor activity, enabling clinical development of SHP2 inhibitors for RAS-driven cancers.
PROTAC-induced degradation of mutant EGFR overcomes osimertinib resistance
Cancer Cell (2021)
Demonstrated PROTAC degraders can overcome drug resistance in EGFR-mutant NSCLC, validating degradation as a next-generation therapeutic strategy.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Sebastian Bauer
University Hospital Essen (Universitätsklinikum Essen)
Suzanne George
Dana-Farber Cancer Institute / Harvard Medical School
Marcia S. Brose
Sidney Kimmel Cancer Center, Thomas Jefferson University
Lori J. Wirth
Massachusetts General Hospital, Harvard Medical School
关注 纳撒尼尔·格雷 的研究动态
Follow Nathanael Gray's research updates
留下邮箱，当我们发布与 Nathanael Gray（Stanford University School of Medicine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment